Translational Research in Veterinary Oncology: From Bench Discoveries to Clinical Applications for Enhanced Cancer Care in Animals
Abstract
The field of veterinary oncology stands at a pivotal juncture, where translational research plays a crucial role in bridging the gap between bench discoveries and clinical applications. With cancer being a leading cause of morbidity and mortality in companion animals, the integration of cutting-edge scientific findings into clinical practice holds immense promise for advancing cancer care and improving outcomes. At the forefront of this endeavor lies a multidisciplinary approach that leverages insights from molecular biology, immunology, genetics, and pharmacology. Through a synergistic collaboration between basic scientists, clinicians, and veterinary oncologists, novel therapeutic strategies are being developed and refined, tailored to the unique biological characteristics of various tumor types encountered in veterinary patients. Key areas of focus in translational research include elucidating the molecular mechanisms underlying cancer initiation, progression, and metastasis, as well as identifying biomarkers for early detection, prognostication, and treatment response assessment. By unraveling the intricate interplay between tumor cells and the host microenvironment, researchers aim to devise targeted therapies that disrupt oncogenic signaling pathways while sparing normal tissues. Immunotherapy represents a paradigm shift in cancer treatment, with recent advances in veterinary oncology mirroring those in human medicine. From checkpoint inhibitors to chimeric antigen receptor (CAR) T-cell therapy, immunomodulatory approaches are revolutionizing the management of certain malignancies, offering new hope for patients previously deemed incurable.
References
[2] Chen, Y.-X.; Wei, C.-X.; Lyu, Y.-Q.; Chen, H.-Z.; Jiang, G.; Gao, X.-L. Biomimetic drug-delivery systems for the management of brain diseases. Biomater. Sci. 2020, 8, 1073–1088.
[3] Chen, L.; Hong, W.; Ren, W.; Xu, T.; Qian, Z.; He, Z. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. Signal Transduct. Target. Ther. 2021, 6, 225.
[4] Zhang, M.; Du, Y.; Wang, S.; Chen, B. A Review of Biomimetic Nanoparticle Drug Delivery Systems Based on Cell Membranes. Drug Des. Dev. Ther. 2020, 14, 5495–5503.
[5] Tariq, H.; Batool, S.; Asif, S.; Ali, M.; Abbasi, B.H. Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. Front. Microbiol. 2022, 12, 790121.
[6] Nooraei, S.; Bahrulolum, H.; Hoseini, Z.S.; Katalani, C.; Hajizade, A.; Easton, A.J.; Ahmadian, G. Virus-like particles: Preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnol. 2021, 19, 59.
[7] Banskota, S.; Raguram, A.; Suh, S.; Du, S.W.; Davis, J.R.; Choi, E.H.; Wang, X.; Nielsen, S.C.; Newby, G.A.; Randolph, P.B.; et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 2022, 185, 250–265.e216.
[8] Zhang, Y.; Xu, Y.; Gao, J. The engineering and application of extracellular matrix hydrogels: A review. Biomater. Sci. 2023, 11, 3784–3799.
[9] Herrmann, I.K.; Wood, M.J.A.; Fuhrmann, G. Extracellular vesicles as a next-generation drug delivery platform. Nat. Nanotechnol. 2021, 16, 748–759.
[10] Kalluri, R.; LeBleu, V.S. The biology, function, and biomedical applications of exosomes. Science 2020, 367, eaau6977.
[11] Bariwal, J.; Ma, H.; Altenberg, G.A.; Liang, H. Nanodiscs: A versatile nanocarrier platform for cancer diagnosis and treatment. Chem. Soc. Rev. 2022, 51, 1702–1728.
[12] Traughber, C.A.; Opoku, E.; Brubaker, G.; Major, J.; Lu, H.; Lorkowski, S.W.; Neumann, C.; Hardaway, A.; Chung, Y.M.; Gulshan, K.; et al. Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice. J. Biol. Chem. 2020, 295, 8252–8261.
[13] Chen, Z.; Chen, X.; Huang, J.; Wang, J.; Wang, Z. Harnessing Protein Corona for Biomimetic Nanomedicine Design. Biomimetics 2022, 7, 126.
[14] Tang, Z.; Xiao, Y.; Kong, N.; Liu, C.; Chen, W.; Huang, X.; Xu, D.; Ouyang, J.; Feng, C.; Wang, C.; et al. Nano-bio interfaces effect of two-dimensional nanomaterials and their applications in cancer immunotherapy. Acta Pharm. Sin. B 2021, 11, 3447–3464.
[15] Liu, Y.; Wang, J.; Xiong, Q.; Hornburg, D.; Tao, W.; Farokhzad, O.C. Nano–Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection. Accounts Chem. Res. 2021, 54, 291–301.
[16] Chen, Z.; Chen, X.; Liu, G.; Han, K.; Chen, J.; Wang, J. Editorial: The Application of Nanoengineering in Advanced Drug Delivery and Translational Research. Front. Bioeng. Biotechnol. 2022, 10, 886109.
[17] Liu, S.; Yu, J.-M.; Gan, Y.-C.; Qiu, X.-Z.; Gao, Z.-C.; Wang, H.; Chen, S.-X.; Xiong, Y.; Liu, G.-H.; Lin, S.-E.; et al. Biomimetic natural biomaterials for tissue engineering and regenerative medicine: New biosynthesis methods, recent advances, and emerging applications. Mil. Med. Res. 2023, 10, 16.
[18] Soprano, E.; Polo, E.; Pelaz, B.; del Pino, P. Biomimetic cell-derived nanocarriers in cancer research. J. Nanobiotechnol. 2022, 20, 538.
